EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 27 (2020) Parasite, 27 (2020) 36 References
Open Access
Issue
Parasite
Volume 27, 2020
Article Number 36
Number of page(s) 10
DOI https://doi.org/10.1051/parasite/2020036
Published online 18 May 2020
  1. An G, Murry DJ, Gajurel K, Bach T, Deye G, Stebounova LV, Codd EE, Horton J, Gonzalez AE, Garcia HH, Ince D, Hodgson-Zingman D, Nomicos EYH, Conrad T, Kennedy J, Jones W, Gilman RH, Winokur P. 2019. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose Escalation Study. Antimicrobial Agents and Chemotherapy, 63, e02255-18. [CrossRef] [PubMed] [Google Scholar]
  2. Assana E, Doba E, Awah-Ndukum J, Soh GB, Mohamadou A, Mebanga AS, Zoli AP. 2018. Formule de barymétrie pour l’estimation du poids chez les zébus Goudali au Cameroun. Bulletin of Animal Health and Production in Africa, 66, 469–480. [Google Scholar]
  3. Awadzi K, Schulz-Key H, Howells RE, Haddock DR, Gilles HM. 1982. The chemotherapy of onchocerciasis. VIII. Levamisole and its combination with the benzimidazoles. Annals of Tropical Medicine and Parasitology, 76, 459–473. [CrossRef] [PubMed] [Google Scholar]
  4. Awadzi K, Hero M, Opoku O, Büttner DW, Gilles HM. 1991. The chemotherapy of onchocerciasis. XV. Studies with albendazole. Tropical Medicine and Parasitology, 42, 356–360. [Google Scholar]
  5. Awadzi K, Edwards G, Duke BO, Opoku NO, Attah SK, Addy ET, Ardrey AE, Quartey BT. 2003. The co-administration of ivermectin and albendazole – safety, pharmacokinetics and efficacy against Onchocerca volvulus. Annals of Tropical Medicine and Parasitology, 97, 165–178. [CrossRef] [PubMed] [Google Scholar]
  6. Bain O. 1981. Le genre Onchocerca : hypothèses sur son évolution et clé dichotomique des espèces. Annales de Parasitologie Humaine et Comparée, 56, 503–526. [CrossRef] [Google Scholar]
  7. Barda B, Ame SM, Ali SM, Albonico M, Puchkov M, Huwyler J, Hattendorf J, Keiser J. 2018. Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. Lancet Infectious Diseases, 18, 864–873. [CrossRef] [Google Scholar]
  8. Basáñez MG, Pion SD, Boakes E, Filipe JA, Churcher TS, Boussinesq M. 2008. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infectious Diseases, 8, 310–322. [CrossRef] [Google Scholar]
  9. Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL, Mazdiyasni H, Kogan L, Barman R, Cleveland C, Booth L, Bensel T, Minahan D, Hurowitz HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G. 2016. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Science Translational Medicine, 8, 365ra157. [CrossRef] [PubMed] [Google Scholar]
  10. Bernigaud C, Fang F, Fischer K, Lespine A, Aho LS, Dreau D, Kelly A, Sutra JF, Moreau F, Lilin T, Botterel F, Guillot J, Chosidow O. 2016. Preclinical study of single-dose moxidectin, a new oral treatment for scabies: efficacy, safety, and pharmacokinetics compared to two-dose ivermectin in a porcine model. PLoS Neglected Tropical Diseases, 10, e0005030. [CrossRef] [PubMed] [Google Scholar]
  11. Boussinesq M, Fobi G, Kuesel AC. 2018. Alternative treatment strategies to accelerate the elimination of onchocerciasis. International Health, 10(Suppl. 1), i40–i48. [CrossRef] [PubMed] [Google Scholar]
  12. Bronsvoort BM, Renz A, Tchakouté V, Tanya VN, Ekale D, Trees AJ. 2005. Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle. Filaria Journal, 4, 8. [CrossRef] [PubMed] [Google Scholar]
  13. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, Foy BD. 2012. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Tropica, 121, 34–43. [CrossRef] [PubMed] [Google Scholar]
  14. Büttner DW, Albiez EJ, von Essen J, Erichsen J. 1988. Histological examination of adult Onchocerca volvulus and comparison with the collagenase technique. Tropical Medicine and Parasitology, 39(Suppl. 4), 390–417. [Google Scholar]
  15. Cady SM, Cheifetz PM, Galeska I. 2013. Veterinary long-acting injections and implants, in Long Acting Animal Health Drug Products, Rathborne MJ, McDowell A, Editors. Springer: Boston, MA. p. 271–294. [CrossRef] [Google Scholar]
  16. Chaccour CJ, Ngha’bi K, Abizanda G, Irigoyen Barrio A, Aldaz A, Okumu F, Slater H, Del Pozo JL, Killeen G. 2018. Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation. Parasites and Vectors, 11, 287. [CrossRef] [Google Scholar]
  17. Cover J, Blanton E, Ndiaye D, Walugembe F, Lamontagne DS. 2014. Operational assessments of Sayana® Press provision in Senegal and Uganda. Contraception, 89, 374–378. [CrossRef] [PubMed] [Google Scholar]
  18. Cunningham CP, Brown JM, Jacobson GA, Brandon MR, Martinod SR. 2006. Evaluation of a covered-rod silicone implant containing ivermectin for long-term prevention of heartworm infection in dogs. American Journal of Veterinary Research, 67, 1564–1569. [CrossRef] [PubMed] [Google Scholar]
  19. Doyle SR, Bourguinat C, Nana-Djeunga HC, Kengne-Ouafo JA, Pion SDS, Bopda J, Kamgno J, Wanji S, Che H, Kuesel AC, Walker M, Basáñez MG, Boakye DA, Osei-Atweneboana MY, Boussinesq M, Prichard RK, Grant WN. 2017. Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Neglected Tropical Diseases, 11, e0005816. [CrossRef] [PubMed] [Google Scholar]
  20. Ebene Njongui J, Onyali Ikechuku O, Mingoas JP, Mfopit Mouliom Y, Aboubakar Dandjouma AK, Manchang TK, Toukala JP, Akuro A, Nwosu CO. 2016. Management of cattle parasitism and use of anthelmintics in mixed farming systems in the Vina Division, Cameroon. International Journal of Livestock Research, 6, 59–72. [CrossRef] [Google Scholar]
  21. Fritz ML, Walker ED, Miller JR. 2012. Lethal and sublethal effects of avermectin/milbemycin parasiticides on the African malaria vector, Anopheles arabiensis. Journal of Medical Entomology, 49, 326–331. [CrossRef] [PubMed] [Google Scholar]
  22. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue Duke BO. 2002. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet, 360, 203–210. [CrossRef] [PubMed] [Google Scholar]
  23. Gaudriault G, Inventor. 2011. Biodegradable drug delivery compositions. US Patent 9,023,897 B2. [Google Scholar]
  24. Gillon JYA, van den Berg F, Dequatre Cheeseman K, Hopchet N, Delhomme S, Peña Rossi C, Monnot F, Strub-Wourgaft N, Rodriguez ML, Don R. 2018. A single-center, first-in-human, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability and pharmacokinetics of escalading doses of emodepside (BAY44-4400) in healthy male subjects. American Journal of Tropical Medicine and Hygiene, 99(Suppl. 4), 168. [CrossRef] [Google Scholar]
  25. Gonzalez AE, Codd EE, Horton J, Garcia HH, Gilman RH. 2019. Oxfendazole: a promising agent for the treatment and control of helminth infections in humans. Expert Review of Anti-Infective Therapy, 17, 51–56. [CrossRef] [PubMed] [Google Scholar]
  26. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC. 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. Journal of Clinical Pharmacology, 42, 1122–1133. [CrossRef] [PubMed] [Google Scholar]
  27. Hübner MP, Martin C, Specht S, Koschel M, Dubben B, Frohberger SJ, Ehrens A, Fendler M, Struever D, Vallarino-Lhermitte N, Gokool S, Townson S, Hoerauf A, Scandale I. 2018. Oxfendazole treatment has a macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca gutturosa adult worm motility in vitro. American Journal of Tropical Medicine and Hygiene, 99(Suppl. 4), 656–657. [Google Scholar]
  28. Kigen G, Edwards G. 2017. Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers. BMC Pharmacology and Toxicology, 18, 20. [CrossRef] [Google Scholar]
  29. Kulke D, Townson S, Bloemker D, Frohberger S, Specht S, Scandale I, Glenschek-Sieberth M, Harder A, Hoerauf A, Hübner MP. 2017. Comparison of the in vitro susceptibility to emodepside of microfilariae, third stage larvae and adult worms of related filarial nematodes. American Journal of Tropical Medicine and Hygiene, 97(Suppl. 5), 563. [CrossRef] [Google Scholar]
  30. Lachau-Durand S, Lammens L, van der Leede BJ, Van Gompel J, Bailey G, Engelen M, Lampo A. 2019. Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. PLoS Neglected Tropical Diseases, 13, e0007026. [CrossRef] [PubMed] [Google Scholar]
  31. Lespine A, Alvinerie M, Vercruysse J, Prichard RK, Geldhof P. 2008. ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends in Parasitology, 24, 293–298. [CrossRef] [PubMed] [Google Scholar]
  32. Makepeace BL, Tanya VN. 2016. 25 years of the Onchocerca ochengi model. Trends in Parasitology, 32, 966–978. [CrossRef] [PubMed] [Google Scholar]
  33. Mounsey KE, Walton SF, Innes A, Cash-Deans S, McCarthy JS. 2017. In vitro efficacy of moxidectin versus ivermectin against Sarcoptes scabiei. Antimicrobial Agents and Chemotherapy, 61, e00381-17. [CrossRef] [PubMed] [Google Scholar]
  34. Nolan TJ, Lok JB. 2012. Macrocyclic lactones in the treatment and control of parasitism in small companion animals. Current Pharmaceutical Biotechnology, 13, 1078–1094. [CrossRef] [PubMed] [Google Scholar]
  35. Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, Nigo MM, Kasonia K, Masembe SL, Mumbere M, Kataliko K, Larbelee JP, Kpawor M, Bolay KM, Bolay F, Asare S, Attah SK, Olipoh G, Vaillant M, Halleux CM, Kuesel AC. 2018. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet, 392, 1207–1216. [CrossRef] [PubMed] [Google Scholar]
  36. Renz A, Trees AJ, Achu-Kwi D, Edwards G, Wahl G. 1995. Evaluation of suramin, ivermectin and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle. Tropical Medicine and Parasitology, 46, 31–37. [Google Scholar]
  37. Roberge C, Cros JM, Serindoux J, Cagnon ME, Samuel R, Vrlinic T, Berto P, Rech A, Richard J, Lopez-Noriega A. 2020. BEPO®: bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation. Journal of Controlled Release, 319, 416–427. [CrossRef] [Google Scholar]
  38. Stewart S, Domínguez-Robles J, Donnelly R, Larrañeta E. 2018. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers, 10, 1379. [Google Scholar]
  39. Sutherland IA, Leathwick DM. 2011. Anthelmintic resistance in nematode parasites of cattle: a global issue? Trends in Parasitology, 27, 176–181. [Google Scholar]
  40. Taylor HR, Trpis M, Cupp EW, Brotman B, Newland HS, Soboslay PT, Greene BM. 1988. Ivermectin prophylaxis against experimental Onchocerca volvulus infection in chimpanzees. American Journal of Tropical Medicine and Hygiene, 39, 86–90. [CrossRef] [Google Scholar]
  41. Taylor MJ, von Geldern TW, Ford L, Hübner MP, Marsh K, Johnston KL, Sjoberg HT, Specht S, Pionnier N, Tyrer HE, Clare RH, Cook DAN, Murphy E, Steven A, Archer J, Bloemker D, Lenz F, Koschel M, Ehrens A, Metuge HM, Chunda VC, Ndongmo Chounna PW, Njouendou AJ, Fombad FF, Carr R, Morton HE, Aljayyoussi G, Hoerauf A, Wanji S, Kempf DJ, Turner JD, Ward SA. 2019. Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Science Translational Medicine, 11, eaau2086. [CrossRef] [PubMed] [Google Scholar]
  42. Tchakouté VL, Bronsvoort M, Tanya V, Renz A, Trees AJ. 1999. Chemoprophylaxis of Onchocerca infections: in a controlled, prospective study ivermectin prevents calves becoming infected with O. ochengi. Parasitology, 118(Pt 2), 195–199. [CrossRef] [PubMed] [Google Scholar]
  43. von Geldern TW, Morton HE, Clark RF, Brown BS, Johnston KL, Ford L, Specht S, Carr RA, Stolarik DF, Ma J, Rieser MJ, Struever D, Frohberger SJ, Koschel M, Ehrens A, Turner JD, Hübner MP, Hoerauf A, Taylor MJ, Ward SA, Marsh K, Kempf DJ. 2019. Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. PLoS Neglected Tropical Diseases, 13, e0007159. [CrossRef] [PubMed] [Google Scholar]
  44. Wahl G, Achu-Kwi MD, Mbah D, Dawa O, Renz A. 1994. Bovine onchocercosis in North Cameroon. Veterinary Parasitology, 52, 297–311. [CrossRef] [PubMed] [Google Scholar]
  45. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG. 2015. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clinical Infectious Diseases, 60, 1199–1207. [CrossRef] [Google Scholar]
  46. Walker M, Pion SDS, Fang H, Gardon J, Kamgno J, Basáñez MG, Boussinesq M. 2017. Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness. Clinical Infectious Diseases, 65, 2026–2034. [CrossRef] [Google Scholar]
  47. World Health Organization. 2012. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation: executive summary. Geneva: World Health Organization. WHO/HTM/NTD/2012.1. [Google Scholar]
  48. Zahner H, Schares G. 1993. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Tropica, 52, 221–266. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.